Innoviva, Inc.
Innoviva is a specialty pharmaceutical company focused on respiratory treatments with minimal direct government dependence and low political engagement.
BusinessWhat INVA does
Innoviva develops and commercializes prescription medications for respiratory diseases, primarily COPD and asthma. Revenue is generated through product sales to healthcare providers and patients via insurance coverage. The company operates with limited direct government contracts but faces standard pharmaceutical pricing and regulatory oversight.
Lifetime Government AwardsINVA federal contracts
INVA doesn't hold direct federal contracts.
Verified via USASpending.gov: $0 reported in direct prime-contract awards. Companies in this position typically sell federal services indirectly through prime contractors and integrators (e.g., Lockheed Martin, Booz Allen, Microsoft Azure) or through commercial channels that don't appear in USASpending data.
Politicians Trading INVAMembers of Congress with recent INVA positions
Congressional TradesWho in Congress is trading INVA
Corporate Insiders · Form 4What CEOs, CFOs, and directors are doing with their own stock
No Form 4 activity recorded in the last 180 days.
Bills to WatchLegislation flagged by our analysis
Political ProfileWhere INVA sits in Washington
Innoviva has minimal lobbying footprint, no campaign donations, and no legislative naming. Stock movement driven primarily by clinical trial results and product sales rather than political events.
Regulatory ExposureThreats & opportunities
Regulatory threats
- drug pricing pressure
- Medicare reimbursement cuts
- FDA approval delays
Regulatory opportunities
- orphan drug designation
- expedited approval pathways
- patent extension
Live signals + predictions for INVA — for Founders
The free page above gives you the public record. Members see the real-time intelligence layer on top of it:
- Live 7-layer signal scores when Congress trades INVA
- Bill Pass Index v2 odds for every bill on the watch list
- Iron Triangle alerts (committee × donor × trade)
- SEC Form 4 cluster detection (CEO + CFO + director buys)
- Whale-Opportunity expected-value ranking
- Custom watchlist alerts via email + Discord